Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: Jongmans who wrote (50)	5/10/2000 10:29:00 AM
From: nigel bates	Respond to of 598

May 10 /PRNewswire/ -- Array BioPharma and Tularik Inc. (Nasdaq: TLRK - news) today announced an agreement for the design and synthesis of a small molecule focused library targeting orphan nuclear receptors. Array BioPharma has created innovations in high-speed synthesis and parallel purification to facilitate the rapid production of high quality, small molecule libraries. Array will couple its expertise in the design and synthesis of small molecule libraries with Tularik's knowledge of nuclear receptors to produce a library focused on creating valuable information and potential leads for this important class of therapeutic targets. Based on analyses of screening data against multiple nuclear receptors, the library may have widespread screening utility. Following a period of exclusivity with Tularik, Array has the right to offer compounds in the library to third parties. ``We are excited about initiating our second agreement with Tularik,'' said Kevin Koch, Ph.D., President and Chief Science Officer at Array. ``This agreement, which exploits our expertise in chemical genomics, is focused on creating powerful tools to both study orphan nuclear receptors and develop novel therapeutic leads.'' ``We are pleased to expand our collaboration with Array BioPharma and believe this collaboration accelerates Tularik's ability to broaden our knowledge of the function and activity of orphan nuclear receptors,'' said Juan C. Jaen, Ph.D., Director of Chemistry. ``Tularik continues to be impressed with Array's ability to create valuable synthetic libraries that complement our internal work in the discovery of novel therapeutics.''